151 related articles for article (PubMed ID: 34570452)
1. DNA Damage Response in Glioblastoma: Mechanism for Treatment Resistance and Emerging Therapeutic Strategies.
Bonm A; Kesari S
Cancer J; 2021 Sep-Oct 01; 27(5):379-385. PubMed ID: 34570452
[TBL] [Abstract][Full Text] [Related]
2. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
[TBL] [Abstract][Full Text] [Related]
3. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Ferri A; Stagni V; Barilà D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664581
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells.
Ha HA; Yang JS; Tsai FJ; Li CW; Cheng YD; Li J; Hour MJ; Chiu YJ
Anticancer Res; 2021 May; 41(5):2333-2347. PubMed ID: 33952458
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of the DNA damage response pathway in glioblastoma.
Seol HJ; Yoo HY; Jin J; Joo KM; Kong DS; Yoon SJ; Yang H; Kang W; Lim DH; Park K; Kim JH; Lee JI; Nam DH
Oncol Rep; 2011 Aug; 26(2):423-30. PubMed ID: 21617879
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
7. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.
Al-Ejeh F; Kumar R; Wiegmans A; Lakhani SR; Brown MP; Khanna KK
Oncogene; 2010 Nov; 29(46):6085-98. PubMed ID: 20818418
[TBL] [Abstract][Full Text] [Related]
9. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance.
Squatrito M; Holland EC
Cancer Res; 2011 Sep; 71(18):5945-9. PubMed ID: 21917735
[TBL] [Abstract][Full Text] [Related]
10. Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis.
Marima R; Hull R; Penny C; Dlamini Z
Mutat Res Rev Mutat Res; 2021; 787():108376. PubMed ID: 34083040
[TBL] [Abstract][Full Text] [Related]
11. DNA damage response and repair in the development and treatment of brain tumors.
Maleki Dana P; Sadoughi F; Mirzaei H; Asemi Z; Yousefi B
Eur J Pharmacol; 2022 Jun; 924():174957. PubMed ID: 35430209
[TBL] [Abstract][Full Text] [Related]
12. DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies.
Mirza-Aghazadeh-Attari M; Ostadian C; Saei AA; Mihanfar A; Darband SG; Sadighparvar S; Kaviani M; Samadi Kafil H; Yousefi B; Majidinia M
DNA Repair (Amst); 2019 Aug; 80():59-84. PubMed ID: 31279973
[TBL] [Abstract][Full Text] [Related]
13. The promise of DNA damage response inhibitors for the treatment of glioblastoma.
Majd NK; Yap TA; Koul D; Balasubramaniyan V; Li X; Khan S; Gandy KS; Yung WKA; de Groot JF
Neurooncol Adv; 2021; 3(1):vdab015. PubMed ID: 33738447
[TBL] [Abstract][Full Text] [Related]
14. Roles of RNA-Binding Proteins in DNA Damage Response.
Kai M
Int J Mol Sci; 2016 Feb; 17(3):310. PubMed ID: 26927092
[TBL] [Abstract][Full Text] [Related]
15. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E
Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534
[TBL] [Abstract][Full Text] [Related]
16. The DNA damage response during mitosis.
Heijink AM; Krajewska M; van Vugt MA
Mutat Res; 2013 Oct; 750(1-2):45-55. PubMed ID: 23880065
[TBL] [Abstract][Full Text] [Related]
17. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
Rasmussen RD; Gajjar MK; Jensen KE; Hamerlik P
Mol Oncol; 2016 May; 10(5):751-63. PubMed ID: 26794465
[TBL] [Abstract][Full Text] [Related]
19. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
[TBL] [Abstract][Full Text] [Related]
20. DNA damage response inhibitors: An avenue for TNBC treatment.
Jin J; Tao Z; Cao J; Li T; Hu X
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]